Upcoming Anticipated Milestones: Initiate patient dosing in the dose confirmation study of AMT-061, data from which will be available by the end of 2018.
Initiate patient enrollment in the lead-in phase of the pivotal study of AMT-061 in the Q3 2018.
Completion of the GLP-safety and toxicology study of AMT-130 and submission of the IND in Huntington’s disease in H2 2018.
Completion of a preclinical therapeutic heart function study of AMT-126 in congestive heart failure in H2 2018.
Expansion of the Company’s early-stage research pipeline.
Subscribe for full text news in your inbox